Enlightenment Research’s Inovio Pharmaceuticals INO Stock Holding History

Enlightenment Research’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,150	Closed	-$160K	–	108
2020 Q3	$160K	Buy	+1,150	New	+$240K	0.47%	63

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Enlightenment Research's INO Position: Q4 2020 in Review

Enlightenment Research sold out of Inovio Pharmaceuticals (INO) in Q4 2020, closing a stake of 1,150 shares — an estimated $160K sold.

Enlightenment Research first reported a position in INO in Q3 2020 and held it in 1 quarter. The position peaked at $160K in Q3 2020. 227 funds tracked by Wall St. Rank hold INO as of Q4 2020.

Enlightenment Research reported no remaining Inovio Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Enlightenment Research sold 1,150 Inovio Pharmaceuticals shares in Q4 2020, an estimated $160K.
Enlightenment Research first reported a position in Inovio Pharmaceuticals in Q3 2020 and held it in 1 quarter.
Enlightenment Research's Inovio Pharmaceuticals position peaked at $160K in Q3 2020.
227 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2020.

Based on Enlightenment Research's 13F filing for Q4 2020, filed 12 Feb 2021.